Abstracts tagged "Vasculitis"

Abstract Number: 0144 • ACR Convergence 2021
Healthcare Utilization and Costs Following Kawasaki Disease in Ontario, Canada
Cal Robinson¹, Rahul Chanchlani², Anastasia Gayowsky³, Elizabeth Darling², Hsien Seow² and Michelle Batthish², ¹The Hospital for Sick Children, Hamilton, ON, Canada, ²McMaster University, Hamilton, ON, Canada, ³ICES, Hamilton, ON, Canada
Background/Purpose: The incidence of Kawasaki Disease (KD) has increased by nearly 50% in Ontario, Canada over the past two decades. Little is known about the…
Abstract Number: 1048 • ACR Convergence 2021
Estimating the Weight of Rheumatologic Diseases in Mortality in Spain: Basic Cause of Death vs Multiple Cause Analysis
ana Perez¹, Fernando Albarran², Cristina Bohorquez², Atusa Movasat², Lucia Ruiz², Paula Pretel², elena Rabadan², Valentina Emperiale², Adrian abbasi³, julio suarez³, lorena montano³, emilio rico³, alfredo prieto⁴, Inmaculada Leon⁵, melchor Alvarez de Mon³ and beatriz perez⁶, ¹Hospital Universitario Príncipe de Asturias. Rheumatology. Medicine Faculty. Alcala University Department., Madrid, Spain, ²Hospital Universitario Príncipe de Asturias, Rheumatology Department, Alcala de Henares, ³Hospital Universitario Príncipe de Asturias, Madrid, Spain, ⁴Faculty of Medicine. Alcala University, Alcala de Henares, Spain, ⁵Communicable Diseases. Instituto de Salud Carlos III, Madrid, Spain, ⁶Department of Epidemiology of Chronic Diseases.National Center of Epidemiology/CIBERESP. Instituto de Salud Carlos III, Madrid, Spain
Background/Purpose: Classical statistics provide information on mortality rates for basic causes of death. Although many inflammatory rheumatic diseases decrease life expectancy, they are generally not…
Abstract Number: 1457 • ACR Convergence 2021
Clinical Heterogeneity of the VEXAS Syndrome: A Case Series
Matthew Koster¹, Taxiarchis Kourelis¹, Kaaren Reichard¹, Tanaz Kermani², David Beck³, Daniela Ospina Cardona⁴, Matthew Samec¹, Abhishek Mangaonkar¹, Kebede Begna¹, Christopher Hook¹, Jennifer Oliveira¹, Samih Nasr¹, Benedict Tiong⁵, Mrinal Patnaik¹, Michelle Burke¹, Clement Michet¹ and Kenneth Warrington⁶, ¹Mayo Clinic, Rochester, MN, ²University of California Los Angeles, West Hills, CA, ³National Institutes of Health, Bethesda, MD, ⁴National Institutes of Health, Germantown, MD, ⁵University of California Los Angeles Medical Center, Culver City, CA, ⁶Mayo Clinic, Rochester, Minnesota
Background/Purpose: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a recently described myeloid-driven autoinflammatory condition caused by somatic mutations affecting methionine-41 (p.Met41) in the…
Abstract Number: 1885 • ACR Convergence 2021
Biological Therapy in Refractory Neurobehçet’s Disease. Multicenter Study of 42 Patients
Alba Herrero-Morant¹, José Luis Martin-Varillas², Vanesa Calvo-Río³, Santos Castañeda⁴, Olga Maíz⁵, Ana Blanco⁶, Julio Sánchez⁷, Norberto Ortego⁸, Enrique Raya⁹, Anahy Maria Brandy-Garcia¹⁰, Alejandro Olive-Marques¹¹, Agueda Prior-Español¹², Clara Moriano¹³, Elvira Díez¹⁴, Rafael Melero¹⁵, Jenaro Enrique Grana Gil¹⁶, Álvaro Seijas-López¹⁷, Ana Urruticoechea-Arana¹⁸, Ángel Ramos-Calvo¹⁹, Concepcion Delgado-Beltran²⁰, Marta Loredo-Martinez²⁰, Eva Salgado²¹, Francisca Sivera²², Ignacio Torre²³, Javier Narvaez²⁴, Jose Luis Andreu²⁵, Olga Martinez²⁶, Ricardo Gómez de la Torre²⁷, Sabela Fernandez-Aguado²⁸, Susana Romero-Yuste²⁹, Gerard Espinosa³⁰, Miguel Ángel gonzalez-Gay³¹ and Ricardo Blanco³, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Sierrallana, Torrelavega, Spain, ³Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Hospital Universitario de la Princesa, Madrid, Spain, ⁵Hospital Universitario de Donostia, San Sebastián, Spain, ⁶Hospital Universitario de Donostia, San Sebastián, ⁷Hospital Universitario 12 de Octubre, Madrid, Spain, ⁸Medicine Department, Universidad de Granada, Granada, Spain, ⁹Hospital San Cecilio, Granada, Spain, ¹⁰Hospital Germans Trias i Pujol, Badalona, Spain, ¹¹Rheumatology Service. Hospital Germans Trias i Pujol, Barcelona, Spain, ¹²Department of Rheumatology, Germans Trias i Pujol. University Hospital, Badalona, Spain, ¹³Hospital Universitario de León, León, Spain, ¹⁴Hospital de León, León, Spain, ¹⁵Complexo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, ¹⁶Hospital Universitario de A Coruña, A Corua, Spain, ¹⁷Hospital Universitario de A Coruña, A Coruña, Spain, ¹⁸H. Can Misses, Elvissa, Spain, ¹⁹Complejo Hospitalario de Soria, Soria, Spain, ²⁰Hospital Clínico Lozano Blesa, Zaragoza, Spain, ²¹Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ²²Hospital Universitario de Elda, Alicante, Spain, ²³Hospital Universitario de Basurto, Bilbao, Spain, ²⁴Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²⁵Hospital Universitario Puerta de Hierro, Madrid, Spain, ²⁶H. Salamanca, Zamora, Spain, ²⁷H. Asturias, Oviedo, Spain, ²⁸Hospital Universitario de Cabueñes, Gijón, Spain, ²⁹Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, ³⁰Hospital Clinic, Barcelona, Spain, ³¹Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Neurobehçet’s disease (NBD) is a severe complication of Behcet's disease (BD). Despite well-established therapies, with glucocorticoids and conventional immunosuppressants (cIS) a significant proportion of…
Abstract Number: 0151 • ACR Convergence 2021
Usefulness of Ultrasound and (FDG) PET/CT to Detect Cranial and Extracranial Artery Involvement in Patients with Suspected Large Vessel Vasculitis
Juan Molina¹, Isabel Castrejón², Javier Rivera², Julia Martínez Barrio², Juan Carlos Nieto², Katerine López², Fernando Montero², Laura Trives Folguera², Carlos González³ and Jose Maria Alvaro-Gracia², ¹Hospital General Universitario Gregorio Maran, Madrid, Spain, ²Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³CEIMI, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: Ultrasound (US) is recommended as the first imaging modality to assess patients presenting with predominantly cranial symptoms of giant cell arteritis (GCA). However, its…
Abstract Number: 1050 • ACR Convergence 2021
Epidemiology and Clinical Features of Ophthalmological Manifestations in Behçet’s Disease: Study of 50 Patients of a Series of 120 Patients in a Region in Northern Spain
Alba Herrero-Morant¹, Guillermo Suárez-Amorín¹, Rosalia Demetrio-Pablo¹, Lara Sánchez-Bilbao¹, Carmen Álvarez-Reguera¹, David Martinez-Lopez¹, Raul Fernandez¹, José Luis Martin-Varillas², Cristina Mata-Arnaiz³, Miguel Ángel gonzalez-Gay⁴ and Ricardo Blanco⁵, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Sierrallana, Torrelavega, Spain, ³Hospital Laredo, Santander, Spain, ⁴Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Ophthalmological involvement is one of the most feared manifestations of Behçet’s disease.The aim of this study was to define the main demographic and clinical…
Abstract Number: 1548 • ACR Convergence 2021
Q Fever as a Mimicker of Rheumatologic Conditions: A Case Series from Two Tertiary Care Academic Centers in Southern California
Manushi Aggarwal and Marven Cabling, Loma Linda University Health, Redlands, CA
Background/Purpose: Q fever, an endemic disease in Southern California, is a zoonosis caused by Coxiella burnetii. The infection can present with multiple non-specific acute and chronic manifestations including fever, headache,…
Abstract Number: 1886 • ACR Convergence 2021
Validation of Angiographic Patterns of Disease in a Turkish Cohort of Patients with Takayasu’s Arteritis
K. Bates Gribbons¹, SEMA KAYMAZ-TAHRA², Fatma Alibaz³, Ertugrul Cagri bolek⁴, Omer Karadag⁵, Burak Ince⁶, Murat Inanc⁷, Sinem Kocaer⁸, Fatos Onen⁹, KENAN AKSU¹⁰, Gokhan Keser¹¹, Askin Ates¹², Ayten Yazici¹³, Ayse Cefle¹³, Nilufer Alpay Kanitez¹⁴, Ahmet Omma¹⁵, Onay Gercik¹⁶, Servet Akar¹⁷, Veli Cobankara¹⁸, Nazife Sule Yasar Bilge¹⁹, Timucin Kasifoglu²⁰, Mete Kara¹¹, Kaitlin Quinn²¹, Peter Grayson²², Peter Merkel²³ and Haner Direskeneli²⁴, ¹McGovern Medical School, Colleyville, TX, ²Marmara University Faculty of Medicine, Rheumatology, Istanbul, Turkey, ³Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, ⁴Vasculitis Translational Research Program, NIAMS, NIH, US, Lanham, MD, ⁵Hacettepe University, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ankara, Turkey, ⁶Istanbul Faculty of Medicine, Istanbul University, Division of Rheumatology, İstanbul, Turkey, ⁷Istanbul University Faculty of Medicine, Istanbul, Turkey, ⁸Dokuz Eylul University, Izmer, Turkey, ⁹Dokuz Eylul University, Izmir, Turkey, ¹⁰EGE UNIV. FACULTY of MEDICINE, IZMIR, Turkey, ¹¹Ege University, İzmir, Turkey, ¹²Ankara University, Ankara, Turkey, ¹³Kocaeli University, Kocaeli, Turkey, ¹⁴Koc University School of Medicine, Istanbul, Turkey, ¹⁵Ankara City Hospital, Istanbul, Turkey, ¹⁶Izmir Katip Celebi University, Izmir, Turkey, ¹⁷Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey, ¹⁸Pamukkale University, Denizli, Turkey, ¹⁹Eskisehir Osmangazi University Medical Faculty, Eskisehir, Turkey, ²⁰Osmangazi University Department of Rheumatology, Eskişehir, Turkey, ²¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ²²National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²³University of Pennsylvania, Philadelphia, PA, ²⁴Marmara University, Istanbul, Turkey
Background/Purpose: Previous studies using computer-driven methods have identified subsets of patients with Takayasu’s arteritis based on angiographic patterns of disease. These subsets were consistent between…
Abstract Number: 0161 • ACR Convergence 2021
Does 18F-FDG-PET/MRI Add Metabolic Information to Anatomic Image in Childhood-onset Takayasu’s Arteritis Patients? A Multicenter Case Series
Gleice Clemente¹, Alexandre Souza², Hilton Leão Filho³, Fernando Coelho³, Carlos Buchpiguel⁴, Marcos Lima⁴, Daniela Petry Pioto⁵, Melissa Fraga¹, Ana Paula Sakamoto⁶, Camila Carneiro⁴, Rosa Pereira⁷, Nadia Aikawa⁷, Clovis Artur Silva⁷, Lucia Campos⁸, Camilla Astley⁹, Bruno Gualano¹⁰ and Maria Terreri¹¹, ¹Universidade Federal de São Paulo, São Paulo, Brazil, ²UNIFESP-EPM, São Paulo, Brazil, ³Universidade de Sao Paulo/Radiology Institute, São Paulo, Brazil, ⁴Universidade de São Paulo/Department of Radiology and Oncology, São Paulo, Brazil, ⁵Pediatric Rheumatology Unit, Universidade Federal de São Paulo, São Paulo, SP, Brazil, ⁶Federal University of So Paulo (UNIFESP), São Paulo, Brazil, ⁷Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁸children's institute, Sao Paulo, Brazil, ⁹University of Sao Paulo, Sao Paulo, Brazil, ¹⁰Universidade de Sao Paulo/Rheumatology Division, São Paulo, Brazil, ¹¹UNIFESP, São Paulo, Brazil
Background/Purpose: The disease activity assessment in c-TA is a challenge in clinical practice, especially in patients who are under immunosuppression. Our aim was to perform…
Abstract Number: 1391 • ACR Convergence 2021
Rituximab Is Superior to Placebo in Polymyalgia Rheumatica Patients: A Double Blind Randomized Controlled Proof of Principle Trial
Diane Marsman¹, Nathan den Broeder², Frank van den Hoogen³, Alfons den Broeder¹ and Aatke van der Maas⁴, ¹Sint Maartenskliniek, Nijmegen, Gelderland, Netherlands, ²Radboud University Medical Centre, Nijmegen, Gelderland, Netherlands, ³Sint Maartenskliniek, Ubbergen, Gelderland, Netherlands, ⁴St Maartenskliniek, Nijmegen, Gelderland, Netherlands
Background/Purpose: Corticosteroids remain the cornerstone of polymyalgia rheumatica treatment, but their use has several disadvantages such as long treatment duration and glucocorticoid-related adverse events.1,2 Data…
Abstract Number: 1564 • ACR Convergence 2021
Nailfold Capillaroscopy Characterization in COVID-19: A Case Control Study
Paola Estefania Bermudez Bermejo¹, RODOLFO JIMENEZ-SOTO¹, Alain Sanchez-Rodríguez¹, Alonso Turrent¹, Daniela Mercado- Velasco¹, Ian Bravo-Lee¹, Mariana Berenice Colli-Cortés², Everardo Alvarez Hernandez³ and MaryCarmen Amigo¹, ¹CENTRO MEDICO ABC, Mexico City, Mexico, ²Hospital Regional "General Ignacio Zaragoza" ISSSTE, Mexico City, Mexico, ³HOSPITAL GENERAL DE MEXICO, Mexico City, Mexico
Background/Purpose: Nailfold capillaroscopy is a relatively easy-to-access, low-cost clinical tool that could help identify early coagulopathy in subjects with SARS-CoV-2, but specific findings vs. controls…
Abstract Number: 1887 • ACR Convergence 2021
Evidence-Based Behçet’s Disease Activity Scale (EBDA) – A New Instrument with Improved Acuity for Major Organ Disease Activity and Remission Depth Assessment
Maria Caterina Lagdameo¹, Hyungrok Do² and Johannes Nowatzky¹, ¹Division of Rheumatology, New York University School of Medicine, New York, NY, ²Department of Population Health, NYU School of Medicine, New York
Background/Purpose: Most current Behçet’s disease (BD) activity assessment tools are strongly based on patient-reported symptoms and findings allowing a wide range of observer-dependent interpretations and…
Abstract Number: 0163 • ACR Convergence 2021
Diagnosis of Giant Cell Arteritis in Spain: Data from the ARTESER Registry
Eugenio De Miguel¹, Jesús T. Sánchez-Costa², Javier Narvaez³, Miguel Ángel gonzalez-Gay⁴, Noemí Garrido-Puñal⁵, Paula V. Estrada-Alarcon⁶, Iñigo Hernández-Rodríguez⁷, Elisa Fernández-Fernández⁸, María T. Silva-Diaz⁹, Jesús A. Valero-Jaimes¹⁰, Ismael González-Fernández¹¹, Julio Sánchez¹², Judit Lluch¹³, Eva Galindez-Agirregoikoa¹⁴, Javier Mendizábal-Mateos¹⁵, Luis Rodriguez Rodriguez¹⁶, Javier Loricera García¹⁷, Alejandro Muñoz¹⁸, Santos Castañeda¹⁹, Patricia Moya²⁰, Patricia Morán-Álvarez²¹, Vanessa A. Navarro-Angeles⁶, Joan Calvet-Fontova²², Ivette Casafont²³, Francisco Ortiz-Sanjuán²⁴, Selene Labrada-Arrabal²⁵, Cristina Campos-Fernández²⁶, María Alcalde-Villar²⁷, Antonio Juan-Mas²⁸ and Ricardo Blanco²⁹, ¹Hospital Universitario La Paz, Madrid, Spain, ²Spanish Society of Rheumatology, Madrid, Spain, ³Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁵Hospital Universitario Virgen del Rocío, Sevilla, Spain, ⁶Hospital de Sant Joan Despí Moisès Broggi. Sant Joan Despí, Barcelona, Spain, ⁷Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁸Rheumatology department, La Paz University Hospital, Madrid, Spain, ⁹Complejo Hospitalario Universitario de La Coruña, Coruña, Spain, ¹⁰Hospital Universitario Donostia, Donostia-San Sebasti, Spain, ¹¹Hospital Universitario de León, León, Spain, ¹²Hospital Universitario 12 de Octubre, Madrid, Spain, ¹³Hospital Universitari Bellvitge, Hospitalet de Llobregat, Spain, ¹⁴Hospital Universitario de Basurto, Bilbao, Spain, ¹⁵H. Navarra, Navarra, Spain, ¹⁶Hospital Clinico San Carlos, Madrid, Spain, ¹⁷Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹⁸Hospital Universitario Virgen del Rocío, Sevial, Spain, ¹⁹Hospital Universitario de la Princesa, Madrid, Spain, ²⁰Hospital Sant Pau, Barcelona, Spain, ²¹Hospital Universitario Ramón y Cajal, Madrid, Spain, ²²Hospital Universitari Parc Tauli, Sabadell, Spain, ²³Hospital Universitari Germans Trias i Pujol, Barcelona, Badalona, Spain, ²⁴H. La Fe, Valencia, Spain, ²⁵Hospital del Mar, Barcelona, Spain, ²⁶Consorci Hospital General Universitari de Valencia, Valencia, Spain, ²⁷Hospital Universitario Severo Ochoa, Leganés, Spain, ²⁸Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, ²⁹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: To standardize research studies different classification systems are used. Currently, the ACR Giant Cell Arteritis (GCA) 19901 classification criteria is probably the most widely…
Abstract Number: 1393 • ACR Convergence 2021
All-cause Mortality in a Hospital Ascertained Cohort with Giant Cell Arteritis: A Longitudinal Population-level Data Linkage Cohort Study
Helen Keen¹, Warren Raymond², Susan Lester³, David Preen², Charles Inderjeeth⁴, Catherine Hill⁵ and Johannes Nossent², ¹University of Western Australia, Daglish, Australia, ²University of Western Australia, Perth, Australia, ³Rheumatology Department, The Basil Hetzel Institute, The Queen Elizabeth Hospital, Adelaide, Australia, ⁴University of Western Australia, Nedlands, Perth, Australia, ⁵Queen Elizabeth Hospital, Woodville, Australia
Background/Purpose: Giant Cell Arteritis (GCA) is the most common primary vasculitis in high income countries and ischemic complications of GCA include blindness and stroke. The…
Abstract Number: 1625 • ACR Convergence 2021
Clinical Characteristics of Multisystem Inflammatory Syndrome in Children: A Provincial Cohort
Herman Tam¹, Alison Lopez², Mona Patel², Jonathan Rayment³, Lori Tucker⁴ and Catherine Biggs⁵, ¹Stollery Children's Hospital, University of Alberta, Edmonton, AB, Canada, ²British Columbia Children's Hospital, University of British Columbia, Vancouver, BC, Canada, ³British Columbia Children’s Hospital, University of British Columbia, Vancouver, BC, Canada, ⁴BC Children's Hospital, Vancouver, BC, Canada, ⁵[email protected], Vancouver, BC, Canada
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a post-infectious complication of COVID-19 infection with overlapping features of Kawasaki Disease (KD) and Toxic Shock Syndrome…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].